SYS6042 / CSPC Pharma - LARVOL DELTA

SYS6042, a novel anti-TROP2 pH-sensitive antibody-drug conjugate (ADC) with improved therapeutic window (AACR 2025) - "In clinical, Dato-DXd, Trodelvy and SKB264 showed obvious on-target toxicity or off-target toxicity, which affect clinical development and patient benefit. The highest non-severely toxic dose (HNSTD) for monkeys was defined as 30 mg/kg for repeating dosing. Based on these results, it demonstrates that the novel design of SYS6042 leads to an improved therapeutic window, which would help address unmet needs in the treatments of TROP2-positive tumors."

Oncology • TACSTD2